Skip to main content
OpenTrials
Completed

NCT Number: NCT01667042

Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough

This is a mechanistic research study to evaluate the relationship between cough, reflux, and aspiration in patients with systemic sclerosis (scleroderma).

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients ≥ 18 years old.
  • Fulfilling the American College of Rheumatology criteria for SSc.
  • For ILD subgroup (n=6):
  • An upright chest-roentgenogram (chest x-ray) is abnormal and compatible with an interstitial lung disease.
  • HRCT of the chest confirms the presence of bilateral reticular, ground glass, and/or honeycomb abnormalities that is otherwise unexplained by an alternative process
  • The HRCT fibrosis score must be ≥ 7.
  • The total lung capacity (TLC, measured by body plethysmography) and/or the diffusing capacity of the lung for carbon monoxide (DLCO) is below the predicted normal.
  • The forced vital capacity (FVC) is reduced below the predicted normal.
  • The patient is symptomatic (i.e. dyspnea and/or a chronic cough) for more than 8 weeks that is otherwise unexplained by an alternative mechanism.
  • For No ILD subgroup (n=6):
  • No radiographic evidence of ILD on plain chest x-ray.
  • The HRCT fibrosis score, when performed) must be < 7
  • The TLC and FVC are within their predicted normal.
  • The DLCO is within the predicted normal, except when reduced in isolation by pulmonary hypertension.

Exclusion criteria

  • Active smoking within the 6 months.
  • Pneumonia or bronchitis in past 4 weeks.
  • Active acute illness such as uncontrolled heart failure, infection, or asthma.
  • Use of more than 3 liters per minute (LPM) of oxygen by nasal cannula at rest.
  • Coordinator, investigator, or clinician concerns on the patient's compliance, safety, or in ability to complete study requirements.
  • Morbid condition not expected to live more than 1 year.
  • Alternative cause or diagnosis for the patient's ILD besides SSc.
  • Pregnancy.
  • Obstructive lung disease with an FEV1 (forced expiratory volume in 1 second) to FVC ratio less than 0.7, nor radiographic evidence of emphysema on CT.
  • Planned therapeutic procedures involving the esophagus (e.g. dilation, surgery) prior to completion of study tests

Treatment and study plan

Primary outcomes

  1. Airway pepsin concentration

    Time frame: cross-sectional

    Cross-sectional comparison between airway pepsin level, cough frequency, FVC, DLCO, and CT fibrosis score

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2012
Primary completion
2014
Study completion
2015
First posted
Aug 17, 2012
Registry last updated
Jan 8, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.